Policy & Regulation
Emmes conducts data and statistical analysis for third iteration of Adaptive COVID-19 Treatment Trial using Advantage eClinical system
30 November 2021 -

Emmes, a global, full-service Clinical Research Organisation, announced on Monday that it has carried out the data and statistical analysis for the third iteration of the Adaptive COVID-19 Treatment Trial, utilising its proprietary Advantage eClinical system.

The ACTT-3 trial evaluated the efficiency and safety of interferon beta-1a and remdesivir compared to remdesivir alone in hospitalised adults with COVID-19.

Preliminary data from prior small studies had indicated a potential benefit of interferon beta-1afor COVID-19 patients. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), sponsored a randomised, double-blind, placebo-controlled clinical trial that included 969 subjects at 63 hospitals in five countries, including the United States to assess the combination of interferon beta-1a and remdesivir. The study revealed that the use of both Interferon beta-1a and remdesivir was not superior to remdesivir alone in patients hospitalised with COVID-based pneumonia. The outcomes also showcased that the subgroup of participants receiving high-flow oxygen at randomisation had worse results after treatment with interferon beta-1a compared with those who received placebo.



Related Headlines